Sanofi axes cancer combo, early next-gen diabetes drug

If you’ve been paying attention this week, you’ve seen that nearly every Big Pharma has been sweeping out dead R&D projects: Sanofi, posting its third-quarter data early this morning, is no different.

In its financial results, the French Big Pharma said it was culling a combination therapy of its approved oncology monoclonal antibody (mAb) Libtayo alongside its phase 3 experimental anti-CD38 mAb isatuximab in “advanced malignancies.” The combo had been axed in prostate and lung cancer tests.